ERAS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

Faruqi & Faruqi, LLP is investigating potential claims against Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: 1) ERAS-0015's preclinical data was based on improper comparisons to Revolution Medicines, Inc. ("RevMed") and placed Erasca at risk of violating patent and trade secret protections; and (2) based on the foregoing, Defendants lacked a reasonable basis for their positive statements related to ERAS-0015.

On April 27, 2026, before the market opened, Erasca disclosed in a Form 8-K that it had received a letter from legal counsel for RevMed alleging that Erasca's ERAS-0015 infringes a RevMed patent (U.S. Patent No. 12,409,225) and is connected to alleged trade secret misappropriation, and that Erasca had "improperly compared preclinical data of ERAS-0015 and RMC-6236 in public disclosures." On this news, Erasca's stock price fell $2.34, or approximately 10.9%, from a closing price of $21.49 on April 24, 2026 to close at $19.15 per share on April 27, 2026.

On April 27, 2026, at approximately 4:17 p.m. EDT, Erasca filed a separate Form 8-K reporting preliminary Phase 1 clinical data for ERAS-0015 and disclosing that one patient that received 24 mg of ERAS-0015 had died approximately a month after starting ERAS-0015, classified as a "Grade 3 TRAE of pneumonitis" that "progressed to Grade 5 after withdrawal of supportive care per patient decision," and further stating that comparisons between ERAS-0015 and other product candidates, including RMC-6236, were "not based on any head-to-head clinical trials" and are "inherently limited and such data may not be directly comparable." On this news, Erasca's stock price fell $9.25, or more than 45%, from a closing price of $19.15 per share on April 27, 2026 to close at $9.90 per share on April 28, 2026.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Erasca's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.